Marc Lemann
Overview
Explore the profile of Marc Lemann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
5566
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Amiot A, Setakhr V, Seksik P, Allez M, Treton X, De Vos M, et al.
Am J Gastroenterol
. 2014 Aug;
109(9):1443-9.
PMID: 25091063
Objectives: Although anti-tumor necrosis factor (TNF) therapy is the treatment of choice for perianal fistulizing Crohn's disease (CD), the efficacy and safety of anti-TNF therapy in enterocutaneous fistula (ECF) remains...
2.
Soderman J, Noren E, Christiansson M, Bragde H, Thiebaut R, Hugot J, et al.
World J Gastroenterol
. 2013 Aug;
19(30):4935-43.
PMID: 23946598
Aim: To investigate a possible genetic influence of claudin (CLDN)1, CLDN2 and CLDN4 in the etiology of inflammatory bowel disease. Methods: Allelic association between genetic regions of CLDN1, CLDN2 or...
3.
Jung C, Colombel J, Lemann M, Beaugerie L, Allez M, Cosnes J, et al.
PLoS One
. 2013 Jan;
7(12):e52223.
PMID: 23300620
Background & Aims: Recent studies reported a role for more than 70 genes or loci in the susceptibility to Crohn's disease (CD). However, the impact of these associations in clinical...
4.
Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, et al.
Lancet
. 2012 Oct;
380(9857):1909-15.
PMID: 23063316
Background: Ciclosporin and infliximab are potential rescue treatments to avoid colectomy in patients with acute severe ulcerative colitis refractory to intravenous corticosteroids. We compared the efficacy and safety of these...
5.
DHaens G, Feagan B, Colombel J, Sandborn W, Reinisch W, Rutgeerts P, et al.
Gastroenterology
. 2012 Sep;
143(6):1461-9.
PMID: 23000597
Treatment of inflammatory bowel disease has greatly improved with the development of targeted, monoclonal antibody-based therapies. Tumor necrosis factor antagonists are frequently used to treat patients with Crohn's disease or...
6.
Hebuterne X, Lemann M, Bouhnik Y, Dewit O, Dupas J, Mross M, et al.
Gut
. 2012 Apr;
62(2):201-8.
PMID: 22525883
Objective: To evaluate the efficacy of certolizumab pegol (CZP) in improving endoscopic lesions in patients with active ileocolonic Crohn's disease (CD). Methods: This phase IIIB multicentre open-label clinical trial enrolled...
7.
Savoye G, Salleron J, Gower-Rousseau C, Dupas J, Vernier-Massouille G, Fumery M, et al.
Inflamm Bowel Dis
. 2012 Feb;
18(11):2072-8.
PMID: 22294515
Background: Identification of children with Crohn's disease (CD) at high risk of disabling disease would be invaluable in guiding initial therapy. Our study aimed to identify predictors at diagnosis of...
8.
Amiot A, Allez M, Treton X, Fieschi C, Galicier L, Joly F, et al.
Dig Liver Dis
. 2011 Nov;
44(4):343-9.
PMID: 22100722
Introduction: Enteropathy-associated T-cell lymphoma is a rare form of T-cell lymphoma associated with a poor prognosis and the relative ineffectiveness of standard chemotherapy. The occurrence of haemophagocytic lymphohistiocytosis has been...
9.
Feagan B, Lemann M, Befrits R, Connell W, DHaens G, Ghosh S, et al.
Inflamm Bowel Dis
. 2011 Nov;
18(1):152-60.
PMID: 22038857
Background: Symptom relief is the traditional treatment goal in Crohn's disease (CD). New goals including mucosal healing and bowel preservation are now achievable with tumor necrosis factor (TNF) antagonists. Infliximab...
10.
Travis S, Schnell D, Krzeski P, Abreu M, Altman D, Colombel J, et al.
Gut
. 2011 Oct;
61(4):535-42.
PMID: 21997563
Background: Variability in endoscopic assessment necessitates rigorous investigation of descriptors for scoring severity of ulcerative colitis (UC). Objective: To evaluate variation in the overall endoscopic assessment of severity, the intra-...